Descubre y comparte nuestro conocimiento público

Regional Committee for Africa, 59 ,  [Drug Resistance Related to AIDS, tuberculosis and malaria: issues, challenges and the way forward:]

World Health Organization ,  [What ARV regimen to start with in children older than or equal to three years of age?]

World Health Organization ,  [WHO informal consultation on medium- and long-term priorities for ARV drug optimization: moving towards simplification, harmonization and universal access 29-31 May 2012, Montreux, Switzerland]

Regional Committee for Africa, 59 ,  [Drug Resistance Related to AIDS, tuberculosis and malaria: issues, challenges and the way forward:]

World Health Organization. Communicable Diseases Cluster ,  [Instructions for applying to the green light committee for access to second-line anti-tuberculosis drugs]

World Health Organization. Communicable Diseases Cluster ,  [Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for dots-plus]

World Health Organization ,  [Values and preferences – maternal and child health summary, Consultation for the development of the WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection]

World Health Organization ,  [Preventing stock-outs of antimalarial drugs in sub-Saharan Africa: Novartis's SMS for life]

World Health Organization ,  Suthar, A B ,  Lawn, S D ,  del Amo, J ,  Getahun, H ,  Dye, C ,  Sculier, D ,  Sterling, T R ,  Chaisson, R E ,  Williams, B G ,  Harries, A D ,  Granich, R M ,  [Should early antiretroviral therapy (CD4 > 350 cells/mm3) vs deferred antiretroviral therapy (CD4 < 350 cells/mm3) be used for prevention of tuberculosis?]

World Health Organization ,  Anglemyer, A ,  Horvath, T ,  Autherford, G ,  Penzzato, M ,  [GRADE tables: what ARV regimen to start with in children older than or equal to three years of age?, What ARV regimen to start in children ≥3 years old living with HIV (NVP versus EFV)]